
# Cancer (clinical) DSS



### © Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Downloaded 16-Jul-2024

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

## Cancer (clinical) DSS

### Identifying and definitional attributes

Metadata item type: Data Set Specification

METEOR identifier: 393191

DSS type:

**Registration status:** Health!, Superseded 07/12/2011

**Scope:** This Cancer (clinical) data set specification is not mandated for collection but is

Data Set Specification (DSS)

recommended as best practice if cancer clinical data are to be collected.

The Cancer (clinical) data set underpins the evaluation of cancer treatment services and this can occur at a number of levels; the individual clinician, the health care

institution, at state or territory level and ultimately at a national level.

Clinicians use such data for ongoing patient management and the ability to link patient management to outcomes allows treatments or outcomes to be identified and assessed. Institutions can monitor through-put in their centres for planning and resource allocation purposes to obtain optimum return for cancer expenditure. End-

points can be monitored to ensure that objectives are being met.

The principal aim of good-quality and consistent data is to provide information that can lead to improved quality and length of life for all patients by providing a systematic foundation for evidence-based medicine, informing quality assurance and improvement decisions and guiding successful planning and evaluation of

cancer control activities.

### Collection and usage attributes

Collection methods: This data set is primarily concerned with the clinical use of cancer data. It can also

be used by a wider range of health and health-related establishments that create,

use, or maintain records on health-care clients.

### Source and reference attributes

**Submitting organisation:** National Cancer Control Initiative (NCCI)

Relational attributes

Related metadata references:

Supersedes <u>Cancer (clinical) DSS</u> <u>Health!</u>, Superseded 22/12/2009

Has been superseded by Cancer (clinical) DSS

Health!, Superseded 08/05/2014

### Metadata items in this Data Set Specification

Seq No.	Metadata item	Obligation	Max occurs
-	Cancer staging—cancer staging scheme source edition number, code N[N]	Mandatory	1
-	Cancer staging—cancer staging scheme source, code N	Mandatory	1
-	Cancer staging—staging basis of cancer, code A	Mandatory	1
-	Cancer treatment—cancer treatment type, code N	Mandatory	1

## Seq Metadata item **Obligation Max** No. occurs Cancer treatment—intention of treatment, code N Mandatory 1 DSS specific information: It is used for correlating outcome with original intent of the treatment. Cancer treatment—non-surgical cancer treatment completion date, DDMMYYYY Mandatory 1 DSS specific information: This field must: • be greater than or equal to the date of initial cancer diagnosis, and • be greater than or equal to the date of the initial course of treatment for cancer. This item is collected for the analysis of outcome by treatment type. Collecting dates for radiotherapy treatment and systemic therapy agent treatment will allow evaluation of treatments delivered and of time intervals from diagnosis to treatment, from treatment to recurrence and from treatment to death. Cancer treatment—non-surgical cancer treatment start date, DDMMYYYY Mandatory 1 DSS specific information: This field must: • be greater than or equal to the date of initial cancer diagnosis, and • be less than or equal to the date on which initial treatment for cancer was completed. This metadata item is collected for the analysis of outcome by treatment type. Collecting dates for radiotherapy treatment and systemic therapy agent treatment will allow evaluation of treatments delivered and of time intervals from diagnosis to treatment, from treatment to recurrence and from treatment to death. Cancer treatment—outcome of treatment, code N.N Mandatory 1 DSS specific information: This item is collected for assessing disease status at the end of primary treatment.

Cancer treatment—radiation dose received, total Gray N[NNNN]

Mandatory 1

DSS specific information:

This item is collected for the analysis of outcome by treatment type.

Cancer treatment—radiotherapy treatment type, code N

Mandatory 1

DSS specific information:

This metadata item is collected for the analysis of outcome by treatment type.

Seq No.	Metadata item	Obligation	Max occurs
-	Cancer treatment—surgical procedure date, DDMMYYYY	Mandatory	1
	DSS specific information:		
	This field must be greater than or equal to the date of initial cancer diagnosis.		
	This item is collected for analyses of outcome by treatment type.		
-	Cancer treatment—surgical procedure for cancer, procedure code (ACHI7th edn) NNNN-NN	Mandatory	1
	DSS specific information:		
	This item is collected for determining outcome by treatment type.		
-	Cancer treatment—systemic therapy agent name (primary cancer), antineoplastic drug code (Self-Instructional Manual for Tumour Registrars Book 8 3rd edn) X[X(39)]	Mandatory	1
	DSS specific information:		
	This item is collected for the analysis of outcome by treatment type.		
-	Cancer treatment—target site for cancer treatment, code (ICD-10-AM 7th edn)  ANN{.N[N]}	Mandatory	1
-	Cancer treatment—target site for cancer treatment, code (ICDO-3) ANN	,	1
-	Establishment—organisation identifier (state/territory), NNNNN	Mandatory	1
-	Patient—diagnosis date (cancer), DDMMYYYY	Mandatory	1
-	Patient—diagnosis date (first recurrence of cancer), DDMMYYYY	Mandatory	1
	DSS specific information:		
	This field must:		
	<ul> <li>be greater than the date of diagnosis of cancer</li> <li>be greater than the cancer initial treatment - completion date (if less than cancer initial treatment - completion date, the patient was never disease-free)</li> </ul>		
-	Person (address)—address line, text X[X(179)]	Mandatory	1
-	Person (name)—family name, text X[X(39)]	Mandatory	1
-	Person (name)—given name, text X[X(39)]	Mandatory	1
-	Person with cancer—distant metastasis status, M stage (UICC TNM Classification of Malignant Tumours, 6th edn) code XX	Conditional	1
	Conditional obligation:		
	Collection of this element is conditional on the disease site being listed in the UICC TNM Classification.		
	DSS specific information:		
	For survival analysis adjusted by stage at diagnosis and distribution of cancer cases by type and stage.		

# Seq Metadata item Obligation Max No. occurs

Person with cancer—extent of primary cancer, TNM stage (UICC TNM Classification of Malignant Tumours, 6th ed) code XXXX{[X]XX}

Conditional 1

### Conditional obligation:

Collection of this element is conditional on the disease site being listed in the UICC TNM Classification.

#### DSS specific information:

For survival analysis adjusted by stage at diagnosis and distribution of cancer cases by type and stage.

- Person with cancer—histopathological grade, code N Conditional 1
- Person with cancer—laterality of primary cancer, code [N] Mandatory 1
- Person with cancer—melanoma thickness (at diagnosis), total millimetres NNN.NN
   Conditional 1
- Person with cancer—morphology of cancer, code (ICDO-3) NNNN/N
   Mandatory 1

#### DSS specific information:

This information is collected for the purpose of:

- classifying tumours into clinically relevant groupings on the basis of both their morphology (cell type) and their degree of invasion or malignancy as indicated by the behaviour code component (the last digit of the morphology code);
- monitoring the number of new cases of cancer for planning treatment services.
- Person with cancer—most valid basis of diagnosis of a cancer, code N Conditional 1

### DSS specific information:

Knowledge of the basis of a diagnosis underlying a cancer code is one of the most important aids in assessing the reliability of cancer statistics.

- Person with cancer—number of positive regional lymph nodes, total N[N] Conditional 1
- Person with cancer—number of regional lymph nodes examined, total code N[N] Conditional 1
- Person with cancer—oestrogen receptor assay result, code N Mandatory 1
- Person with cancer—primary site of cancer, code (ICD-10-AM 7th edn) ANN{.N[N]} Conditional 1

#### DSS specific information:

This information is collected for the purpose of:

- classifying tumours into clinically-relevant groupings on the basis of both their site of origin and their histological type
- monitoring the number of new cases of cancer for planning treatment services
- epidemiological studies.

## Seq Metadata item **Obligation Max** No. occurs Person with cancer—primary site of cancer, code (ICDO-3) ANN{.N[N]} Mandatory DSS specific information: This information is collected for the purpose of: · classifying tumours into clinically-relevant groupings on the basis of both their site of origin and their histological type monitoring the number of new cases of cancer for planning treatment services · epidemiological studies. Person with cancer—primary tumour status, T stage (UICC TNM Classification of Mandatory 1 Malignant Tumours, 6th ed) code XX[X] Conditional obligation: Collection of this element is conditional on the disease site being listed in the UICC TNM Classification. DSS specific information: For survival analysis adjusted by stage at diagnosis and distribution of cancer cases by type and stage. Conditional 1 Person with cancer—progesterone receptor assay results, code N DSS specific information: Hormone receptor status is an important prognostic indicator for breast cancer. Person with cancer—region of first recurrence of cancer, code N Mandatory 1 DSS specific information: This item is collected for the analysis of outcome by treatment type. Person with cancer—regional lymph node metastasis status, N stage (UICC TNM Conditional 1 Classification of Malignant Tumours, 6th ed) code XX Conditional obligation: Collection of this element is conditional on the disease site being listed in the UICC TNM Classification. DSS specific information: For survival analysis adjusted by stage at diagnosis and distribution of cancer cases by type and stage. Conditional 1 Person with cancer—solid tumour size (at diagnosis), total millimetres NNN DSS specific information:

and research.

Person—date of birth, DDMMYYYY

This is used to measure the diameter of the largest dimension of breast cancers and other solid neoplasms for patient management, population cancer statistics

Mandatory 1

### Seq Metadata item **Obligation Max** No. occurs - Person—date of death, DDMMYYYY Conditional 1 DSS specific information: This field must be greater than or equal to Date of diagnosis of primary cancer. Person—government funding identifier, Medicare card number N(11) Mandatory 1 Person—person identifier, XXXXXX[X(14)] Mandatory 1 Person-sex, code N Mandatory 1 Person-sex, code N Mandatory 1